UBS Upgrades Johnson & Johnson (JNJ) to Buy
More News related to JNJ
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
- Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
- LecTec Corporation and Endo Pharmaceuticals Inc. Settle Patent Dispute
- Longer Prescribed Replacement Intervals Leads to More Stretching of Frequent Replacement Contact Lenses
UBS upgrades Johnson & Johnson (NYSE: JNJ) from Neutral to Buy, citing long term value.
For more analyst ratings on JNJ click here.
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
Related Categories
UpgradesStocks Mentioned
-0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
